viruses Archives -

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s

Reconfiguring COVID and influenza vaccines for long-term effectiveness

https://pharmaphorum.com/r-d/reconfiguring-covid-and-influenza-vaccines-for-long-term-effectiveness/

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections,

Poolbeg licences candidate for broad-spectrum respiratory infections

https://pharmaphorum.com/news/poolbeg-licences-candidate-for-broad-spectrum-respiratory-infections/

President Donald Trump thrust a decades old malaria drug called chloroquine into the forefront of efforts to treat

Trump pledges access to malaria drug chloroquine for COVID-19

https://pharmaphorum.com/news/trump-pledges-access-to-malaria-drug-chloroquine-for-covid-19/

ViiV Healthcare has fulfilled its pledge of submitting its new HIV drug fostemsavir for approval before year end,

ViiV presses go on FDA filing for first-in-class HIV drug fostemsavir

https://pharmaphorum.com/news/viiv-presses-go-on-fda-filing-for-first-in-class-hiv-drug-fostemsavir/

Roche’s new influenza drug Xofluza can dramatically prevent the spread of the virus when used as a preventive

Roche’s Xofluza limits spread of flu virus, says new study

https://pharmaphorum.com/news/roches-xofluza-limits-spread-of-flu-virus-says-new-study/

ViiV Healthcare has new data on its first-in-class HIV drug fostemsavir that back up its long-term effects, and

ViiV’s first-in-class HIV drug on course for filings this year

https://pharmaphorum.com/news/viivs-first-in-class-hiv-drug-on-course-for-filings-this-year/

Join the 4th Oncolytic Virotherapy Summit in Boston

The 4th Annual Oncolytic Virotherapy Summit – Boston 2018

https://pharmaphorum.com/events/4th-oncolytic-virotherapy-summit-2018/

viruses